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Summary
Mevalonate kinase (MKase) deficiency (MKD) is a rare
autosomal recessive disorder in the pathway of choles-
terol and nonsterol isoprenoid biosynthesis. Thus far,
two disease-causing missense alleles have been identified,
N301T and A334T. We report four additional muta-
tions associated with MKD: L264F, T243I, L265P, and
I268T, the last found in a patient of Mennonite ancestry.
Electrophoretic analysis of bacterially expressed wild-
type and mutant MKase indicated that I268T and T243I
mutants produced normal or somewhat reduced
amounts of MKase protein; conversely, L264F and
L265P mutations resulted in considerably decreased, or
absent, MKase protein. Immunoblot analysis of MKase
from all patients suggested that the MKase polypeptide
was grossly intact and produced in amounts comparable
to control levels. Three mutations resulted in signifi-
cantly diminished MKase enzyme activity (!2%),
whereas the I268T allele yielded ∼20% residual enzyme
activity. Our results should allow more-accurate iden-
tification of carriers and indicate a mutation “cluster”
within amino acids 240–270 of the mature MKase
polypeptide.
Introduction
Mevalonate kinase (MKase; MIM 251170;
E.C.2.7.1.36) deficiency (MKD) is an inborn error of
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metabolism in the early region of the cholesterol and
nonsterol isoprenoid biosynthetic pathway (Hoffmann
et al. 1993). MKase phosphorylates 3,R-mevalonic acid
to produce 5-phosphomevalonic acid, a pivotal com-
pound in cholesterol and isoprenoid synthesis. In ad-
dition to cholesterol, subsequent steps in the metabolism
of mevalonate generate isopentenyl tRNA, dolichol, ubi-
quinones, and Heme A, as well as farnesylated and ger-
anylgeranylated proteins. Because these intermediates
have critical roles in intermediary metabolism, infor-
mation on the production and disposition of 5-phos-
phomevalonic acid is of interest.
The pathology of MKD is multisystemic, with con-
siderable phenotypic variability. In 19 patients, clinical
findings include mild-to-moderate psychomotor retar-
dation, failure to thrive, hypotonia, ataxia, anemia, he-
patosplenomegaly, dysmorphic features, cataracts, lym-
phadenopathy, myopathy, and fat malabsorptive enter-
opathy. The course of the disease has been fatal for about
half of these patients, whereas others have reached late
adolescence or early adulthood.
The highly regulated reaction prior to MKase is cat-
alyzed by 3-hydroxy-3-methylglutaryl (HMG) CoA re-
ductase. A biochemical hallmark ofMKD is significantly
increased levels of mevalonic acid in urine, 0.9–56 mol/
mol creatinine (normal ! 0.003 mol/mol creatinine).
HMG CoA reductase is up-regulated in patients with
MKD and cannot be completely suppressed even with
the administration of potent HMG-CoA reductase in-
hibitors. Although the accumulation of mevalonic acid
in tissues is likely to contribute to disease pathophy-
siology, patients have decompensated when given drugs
whose pharmacologic action is inhibition of HMG-CoA
reductase (Hoffmann et al. 1993). This may indicate that
overaccumulation of mevalonic acid could ameliorate
some aspects of the symptoms (Gibson et al. 1990).
To elucidate the underlying mechanisms associated
with MKD, we have undertaken molecular genetic anal-
yses in affected individuals. The human MKase cDNA
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was cloned, and the first disease-linked mutation in the
index patient (an asparagine to threonine substitution
at position 301) was identified (Hoffmann et al. 1986;
Schafer et al. 1992). More recently, we identified an al-
anine to threonine substitution at amino acid 334 that
significantly altered R,S-mevalonate binding (Hinson et
al. 1997a). We now present four new mutations in six
patients (from four families) with MKD. We have iden-
tified the second disease-associatedmutation in the index
patient as an isoleucine to threonine substitution at po-
sition 268 (I268T), which was also detected as one allele
in a patient of Mennonite ancestry. AlthoughMennonite
ancestry is not acknowledged in the family of the index
patient, the surname of the maternal side of the family
is closely linked to the Mennonite community. To verify
that the I268T allele was disease linked, we performed
extensive pedigree analyses by using enzymatic and se-
quencing methods to determine the transmission of this
allele in the family of the index patient. The three re-
maining mutations clustered in close proximity to this
region at amino acids 243, 264, and 265. Bacterial-ex-
pression analysis and subsequent enzymatic analysis ver-
ified the disease-causing nature of these mutations. The
present report summarizes our findings.
Material and Methods
Material
Material was purchased from manufacturers as fol-
lows: custom synthesized gel-purified oligonucleotides,
chemically competent Escherichia coli DH5a, Moloney
murine leukemia virus (MMLV) reverse transcriptase,
deoxynucleotides, and T4 DNA ligase (Gibco-BRL); Se-
quenase DNA sequencing kit, Thermosequenase se-
quencing kit (Amersham/U.S. Biochemical); Expand*
DNA polymerase, restriction endonucleases, and RNase
inhibitor (Boehringer Mannheim); a-35S-dATP (58 mCi/
mmol) and 33P-ddNTPs (Amersham/Lifescience); Kodak
Biomax film, VWR; Qiaex II DNA isolation kit and Taq
polymerase (Qiagen); OptiMem tissue culture media
(Life Technologies); and expression plasmid pGEX 4T-
3 and GST purification kit (Pharmacia). All other rea-
gents were of the highest purity available. The use of
cultured cells derived from patients was submitted and
approved by the institutional review board on human
subjects of the Baylor University Health Care Campus,
Dallas. Consent from all family members of patient 1
was obtained prior to the collection of blood specimens.
RNA Extraction
Patient lymphoblasts or fibroblasts were grown in
RPMI media supplemented with 20% FCS , l-glutamine,
and streptomycin/kanamycin until confluent. The cells
were harvested by centrifugation and washed three times
at room temperature with PBS. The supernatant was
decanted and the cell pellet used immediately or stored
at80C. RNA was extracted by adding 1–3 ml phenol,
0.1–0.3 ml 2 M sodium acetate (pH 4), and 1–3 ml of
a solution composed of 4 M guanidine thiocyanate, 25
mM sodium citrate (pH 7), and 7.5 mM b-mercapto-
ethanol to each pellet. The cells were resuspended in this
solution and passed through a syringe fitted with a
21–25-gauge needle to shear genomic DNA. The sus-
pension was divided into 1-ml aliquots, and 0.1 ml chlo-
roform was added to each. The samples were mixed and
incubated on ice for 15–30 min. The samples were cen-
trifuged at 12,000 g and 4C for 20 min. The aqueous
phase was transferred to a 1.5-ml microcentrifuge tube
and 0.5 ml isopropanol was added. The samples were
precipitated at20C for 1–24 h. The RNAwas pelleted
by centrifugation for 30 min at 12,000g and washed
with 70% ethanol. The pellet was dried and resuspended
in 50–100 ml H2O.
Reverse Transcription-PCR for Sequence and Cloning
Analysis
First-strand cDNA was synthesized by incubation of
5–10 mg RNA with 27.5 ml H2O at 90C for 5–10 min
to denature RNA secondary structure. Samples were
quick chilled on ice for 2 min. The samples were cen-
trifuged briefly. Two microliters of MMLV reverse tran-
scriptase, 0.5 ml 0.1 M DTT, 10 ml first-strand RT buffer,
2 ml 10-mM nucleotides, 0.5 ml RNase inhibitor, and 20
pmol MK5 primer were added to each and were incu-
bated at 42C for 1–2 h. MK5, a downstream gene-
specific antisense primer, had the following sequence: 5′-
GGCTCGAGCACAGAGTCGAACTGCAGCC-3′. The
samples were ethanol precipitated for 1–24 h at 20C
with 0.1 vol 3-M sodium acetate (pH 4) and 2 vol ab-
solute ethanol. The cDNAwas pelleted by centrifugation
for 10 min at 12,000 rpm and was washed with 70%
ethanol. The samples were dried and resuspended in 80
ml H2O.
Two sets of PCR were performed with two sets of
primers to overlap the MKase cDNA. MK4 and MK2
primers were used to amplify 25 nucleotides of the 5′-
untranslated region of the cDNA, with extension
through nucleotide 993 of the coding region. MK1 and
MK3 primers were used to amplify nucleotides
468–1220, with the stop codon ending at nucleotide
1191. The MK4 primer contained an EcoRI site on the
5′ end with the sequence: 5′-GGGAATTCAGGATTC-
CCAGGAGCCATG-3′. MK2 was an antisense down-
stream primer with the sequence: 5′-CAGCTTGCTG-
TGAAGTCCGCGG-3′. MK1 was a sense primer with
the sequence: 5′-GGATCCCTCCTGACTGTGTGCAG-
3′. MK3 was a antisense downstream primer containing
a XhoI restriction site on the 3′ end with the sequence:
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Table 1
Mutations Identified in Cultured Cells Derived from
MKD Patients and Residual Activity of the
Corresponding Recombinant Glutathione S-
Transferase Fusion Proteins
Patient and
Allelesa
Fusion Protein
Enzyme Activityb
1:
I268T 2.43  .41 (n  9)
N301T .19  .04 (n  4)
2:
T243I .20  .04 (n  3)
L265P None detected (n  3)
3a–c:c
L264F .04  .001 (n  4)
Allele 2 Unknown
4:
I268T 2.43  .41 (n  9)
Allele 2 Unknown
5a and 5b:c
A334T .26  .02 (n  6)d
Control 13.0  1.1 (n  30)e
a Clinical details have been reported for patient 1
(Hoffmann et al. 1986), patient 2 (Kozich et al. 1991)m
patients 3a–c (Mancini et al. 1993), patient 5a, and pa-
tient 5b (Hoffman et al. 1993). Alleles refer to the cor-
responding amino acid of the polypeptide, with wild-
type amino acid on the left and resulting mutant amino
acid on the right (single letter designation).
b The letter “n” denotes number of determinations
on different days; all values presented are mean SEM
(standard error of the mean).
c Patients 5a and 5b are siblings. Preliminary results
indicate that two additional unrelated siblings also have
the L264F allele in a homozygous pattern (J. L. Shaw
and K. M. Gibson, unpublished data).
d See Hinson et al. (1997a).
e Range 7.0–32.8 mmol/min/mg protein.
5′-GGCTCGAGGCTGCAGTGTCGTGGGCTCCTCT-
CAG-3′.
One-eighth of the RT reaction was used in each PCR
reaction. The following were added to each reaction
mixture: 5 ml 10X PCR–reaction buffer containing 1.5
mM Mg2Cl, 10 pmol each primer, and 0.5 ml 10-mM
nucleotides, in a final volume of 50 ml. To prevent am-
plification of non-MKase cDNA, 1.7 U EXPAND poly-
merase was not added until the first annealing step of
PCR. Forty cycles of PCR were performed on the cDNA,
with the following profile: 4-min hot start at 95C; step
1, 94C for 1 min; step 2, 57C for 1 min; step 3, 72C
for 1 min; step 4 for 40 cycles, followed by step 5, 72C
for 5 min; and step 6, 4C. A 15–20-ml aliquot of the
PCR reaction was analyzed on a 0.7% agarose gel. The
correctly sized PCR products (1,020 and 752 bp, re-
spectively) were excised and extensively purifiedwith the
QiaEx II DNA purification kit.
Both sets of PCR products were directly sequenced
and compared with the wild-type sequence in a search
for disease-linked alterations. If amutationwas detected,
the PCR product containing that mutation was cassette-
ligated into the wild-type MKase cDNA in the expres-
sion vector pGEX 4T-3, after excision of the wild-type
fragment.
PCR Amplification of the MKase cDNA for MvaI
Digestion
One mutation that we identified, the threonine to
isoleucine substitution at amino acid 243 (discussed
later) was further analyzed in patient and parents by
using restriction digestion with MvaI. An additional
PCR was done to produce a 714-bp band for digestion
with this restriction endonuclease. The primers used
were sense, 5′-CTGGATATCGTAGTGTGGTCGGA-
3′ and antisense, 5′-GTCAAAGCCACAGCTGGTCA-
G-3′. This 714-bp product contained nucleotide 728
and only seven of the 12MvaI sites within the MKase-
coding region. Digestion of this product provided a
readily distinguishable pattern for the T243I mutation
at nucleotide 728 (CrT substitution).
Cloning, Sequencing, and MvaI Digestion
Chemically competent E. coli DH5a cells were used
for transformation. Clones were completely sequenced
to verify that the mutation of interest was the only mu-
tation introduced. Sequencing was done with the Ther-
mosequenase kit (Amersham) according to the manu-
facturer’s protocols. pGEX vector primers, as well as
internal primers, were used for sequencing. The CrT
mutation at nucleotide 728 resulted in the loss of one
MvaI restriction site. Purified PCR products, derived
from patient 2 (table 1) and the parents, were digested
with 20 U MvaI at 37C for 2 h and analyzed on a 3%
(3:1) agarose gel (NuSieve).
Protein Expression, Enzyme Assay, SDS-PAGE, and
Protein Alignment
Expression of mutant cDNAs was used to assess the
effect of identified mutations on MKase enzyme activity.
Expression was performed with the glutathione S-trans-
ferase fusion vector pGEX 4T-3 system (Pharmacia)
(Chambliss et al. 1995, 1996). The recombinant-fusion
proteins were purified with glutathione Sepharose beads,
as described by the Pharmacia GST-fusion batch-puri-
fication protocol, and enzyme activity was determined
immediately after purification.
MKase activity for purified recombinant enzymes was
determined with use of a standard spectrophotometric
assay, described elsewhere by Hinson et al. (1997b). To
determine MKase enzyme activity in extracts of lym-
phocytes isolated from whole blood, a radiometric assay
was used as described elsewhere by Gibson et al. (1989).
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As control for tissue viability in lymphocyte prepara-
tions, propionyl-coenzyme A carboxylase (PCC) was as-
sayed with use of a standard 14C-bicarbonate fixation
assay, with propionyl-coenzyme A as substrate (Gibson
et al. 1996). Purified wild-type and mutant recombinant
proteins were analyzed on a 10% SDS-polyacrylamide
gel with visualization by Coomassie staining, to deter-
mine the effect of inherited mutations on protein pro-
duction. Protein alignments were performed by use of
the Hitachi MacDNAsis (v. 3.6).
Immunoblotting
SDS-PAGE and immunoblotting were performed as
described elsewhere by Biardi et al. (1994), with the
following modifications: cell extracts from cultured lym-
phoblasts and fibroblasts of patients were obtained by
homogenization in buffer (50 mM KH2PO4, 30 mM
EDTA, 200 mM NaCl, and 10 mM DTT [pH 7.0]) sup-
plemented with 0.2% triton X-100. Cellular debris was
removed by centrifugation. Protein concentrations were
determined by use of a BCA kit (Pierce), with BSA as
standard.
For western blotting, ∼0.2 mg protein per sample was
electrophoresed on a 10% SDS-polyacrylamide gel. The
primary antibody was a polyclonal antipeptide antibody
produced in rabbit against the C-terminal region of
MKase, as described elsewhere (Biardi et al. 1994). The
secondary antibody was a protein A-HRP conjugate
(Bio-Rad). Washes were performed in phosphate-buf-
fered saline tween (0.02 M KH2PO4, 0.5 M NaCl, and
0.05 M Tween 20), with a total of three washes for 5
min each after incubation of the primary antibody, and
three washes at 30 min each after incubation with sec-
ondary antibody. Immunoreactive bands were visualized
with the ECL kit (New England Nuclear).
Results
Clinical Findings in Patients
Clinical summaries have been presented on all patients
described in this report except patient 4, who has not
been reported. In brief, patient 1 presented with severe
failure to thrive, developmental delay, anemia, hepatos-
plenomegaly, central cataracts, and dysmorphic features
(Hoffmann et al. 1986). Patient 2 suffered severe psy-
chomotor retardation, hypotonia, tremor, ataxia, nys-
tagmus, failure to thrive, and agenesis of the vermis cer-
ebelli with cerebellar atrophy (Kozich et al. 1991).
Patients 3a and 3b were two of a three-patient sibship.
All three siblings manifested failure to thrive, suscepti-
bility to infections, hepatosplenomegaly, cataracts, and
psychomotor retardation. Dysmorphic features were ap-
parent in two of three sibs (Mancini et al. 1993). Patients
5a and 5b (siblings, male and female) manifested recur-
rent febrile crises, hypotonia, failure to thrive, ataxia,
cerebellar atrophy, and psychomotor retardation.
Identification and Inheritance of an I268T Mutation in
Patient 1 and 4
A TrC mutation was identified at nucleotide 803 by
direct sequencing of amplified cDNAs derived from two
MKD patients (patient 1 and 4) in different families
(table 1). This mutation resulted in substitution of thre-
onine for isoleucine at amino acid 268 (I268T). DNA
sequencing revealed that patient 4, who is of Mennonite
descent, was a compound heterozygote, with the I268T
mutation as one disease-associated allele. The father of
patient 4 carried the I268T allele, and the mother had
wild-type sequence at this position (data not shown).
Direct sequencing revealed that the index MKD patient
(patient 1) also harbored the I268T allele, confirming
him as a compound heterozygote of I268T and N301T
mutations (table 1). Direct sequencing of amplified
cDNAs revealed that the mother of patient 1 contributed
the I268T allele, whereas the father had wild-type se-
quence at this position.
Because the cDNA sequence of MKase is GC-rich,
significant compressions could occur during DNA-se-
quence analysis. Since the I268T allele had not been
detected in the mother of patient 1 in our earlier study
of this family (Schafer et al. 1992), we sought to verify
that the I268T allele was not simply a common poly-
morphism. Moreover, because this mutation was de-
tected in a patient of Mennonite ancestry, and it is prob-
able that we may again encounter the mutation in this
population, it was important to verify the causative na-
ture. The maternal side of the family of patient 1 was
amenable to DNA and enzyme analysis, and 30 blood
specimens were obtained for verification of the I268T
allele in this cohort (fig. 1). Comparison of enzyme anal-
yses and direct DNA sequencing, depicted in figure 1,
showed very good agreement for 11 of 12 family mem-
bers from the maternal side of the family of patient 1.
Although the results of enzyme studies for the maternal
great-grandfather were unclear, direct sequence analysis
verified that he carried the I268T allele. Two of the fam-
ily members were known carriers of the previously iden-
tified N301T mutation (fig. 1) and thus served as neg-
ative controls (i.e., individuals with intermediate enzyme
activity), whereas three other individuals served as pos-
itive controls (i.e., individuals expected to display wild-
type levels of enzyme activity) having entered the family
through marriage (Goebel-Schreiner et al. 1995).
The family of patient 1 does not acknowledge any
known Mennonite ancestry, although they live in a com-
munity with a considerable Mennonite Amish popula-
tion. In addition, the maternal great-grandfather of pa-
tient 1 has the same surname as the Mennonite patient
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Figure 2 MvaI restriction digestion of cDNAs derived from cul-
tured cells of patient 2 and parents for analysis of the T243I allele.
The size of the original PCR-derived ampliconwas 714 bp, as described
in Material andMethods. Restriction digestion of this amplicon results
in 7 products at 241, 141, 102, 88, 71, 62, and 8 bp, respectively,
corresponding to 6 MvaI sites. The T243I allele results in the loss of
an MvaI site, creating a new product at 190 bp. Heterozygosity for
the T243I allele produces a 190-bp band along with the wild-type
pattern. Lane contents of the gel were as follows: lane 1, DNA mo-
lecular-weight standard; lane 2, blank; lane 3, mother of patient 2;
lane 4, father of patient 2; lane 5, patient 2.
Figure 1 Maternal pedigree of the index family with MKD. White cells were isolated from whole blood for I268T mutation screening
in conjunction with MKase enzyme assay. Sequencing and enzyme determinations represent the mean of at least duplicate determinations.
Numeric values represent the mean ratio of MKase activity to the marker enzyme, PCC. The ratio is used to correct for variation in white-cell
isolation, sonication, and other mechanical manipulations. The proband is indicated with the arrow. His father and brother are carriers of the
N301T mutation and serve as internal controls ( ) for carrier detection by enzyme assay. Individuals whose enzyme ratio is depicted inn  2
parentheses were not family related and thus served as positive controls ( ) for enzyme analyses. N301T asparagine to threoninemutationn  3
at amino acid 301; I268T  isoleucine to threonine substitution at amino acid 268; InAb  induced abortion; SpAb  spontaneous abortion;
SB  stillbirth. The proband is a compound heterozygote of N301T/I268T mutations.
4 in our studies. We are currently looking for nearby
polymorphic markers to test this further by haplotype
analysis.
Identification and Inheritance of T243I and L265P
Mutations in Patient 2
Sequencing of amplified cDNAs derived from cultured
cells of patient 2 revealed two putative disease-linked
mutations. A nucleotide 728 CrT mutation converted
threonine to isoleucine (T243I), and a nucleotide 794
TrC mutation resulted in substitution of proline for
leucine at position 265 of the polypeptide sequence
(L265P) (table 1). The T243I allele was amenable to
restriction-digestion analysis, as the nucleotide substi-
tution resulted in the loss of one MvaI restriction site.
After PCR amplification for restriction digestion (see
Material and Methods), analysis withMvaI verified that
the father of patient 2 contributed the T243I allele,
whereas the mother had wild-type sequence and a nor-
mal MvaI digest pattern (fig. 2). Direct sequencing of
cDNAs derived from cultured cells of the parents of pa-
tient 2 revealed the CrT conversion at nucleotide 728
in the father and the TrC substitution at nucleotide 794
in the mother (data not shown).
Identification of an L264F Mutation in Three Siblings
(Patients 3a, 3b, and 3c)
Sequencing of amplified cDNAs derived from cultured
cells of three affected siblings (table 1) revealed a CrA
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transversion at nucleotide 790 resulting in a substitution
of phenylalanine for leucine at amino acid 264 (L264F).
Parents were unavailable for testing, and a second dis-
ease-linked allele has not been detected.We hypothesized
that this allele was deleterious because it was not de-
tected in 150 control samples and because it occurred
in a region of conservation for a branched-chain amino
acid (fig. 4). We have recently identified the L264F allele
in two affected male siblings, inherited in a homozygous
pattern (J. L. Shaw and K. M. Gibson, unpublished
data).
Enzyme Assay, SDS-PAGE, and Protein Alignment of
Purified Recombinant Proteins
Recombinant MKase proteins were assayed spectro-
photometrically (Hinson et al. 1997b). SDS-PAGE anal-
ysis of the purified recombinant-fusion proteinswith glu-
tathione S-transferase is shown in figure 3. The deduced
Mr of the fusion protein with glutathione S-transferase
is ∼74 kDa. As shown in figure 3, only the protein con-
taining the T243I mutation produced a normal amount
of fusion protein, with wild-type fusion protein in lanes
1 and 4 for comparison. The protein containing the
I268T allele had a reduced amount of protein (!50%
of control), whereas the protein containing the L264F
mutation had markedly reduced protein (!10% of con-
trol), which presented as a doublet on the gel. Lowered
amounts of protein and altered product sizes suggested
enhanced protein lability, at least in extracts of E. coli.
The L265P mutation resulted in almost complete ab-
sence of detectable MKase fusion protein. Of the four
mutations identified, only the I268T protein displayed
modest amounts of residual MKase activity (∼20% of
wild-type activity; the remaining three mutations re-
sulted in enzyme preparations with !2% residual en-
zyme activity [table 1]).
Immunoblot Analysis of MKase in Cultured Cells
Derived from Patients
To assess the effect of mutations on protein stability
in cultured cells from patients, immunoblot (western)
analysis was performed. As shown in figure 5, cell ex-
tracts for all patients showed amounts of MKase protein
(∼Mr 42 kDa) that were comparable to control. For com-
parison with table 1 and figure 3, the lane contents in
figure 5 were as follows: lane 1, patient 1 (see table 1);
lane 2, patient 2; lane 3, patient 4 (see table 1); lane 4
and 5, patient 3a and 3b (see table 1; patient 3c was
not analyzed); and lane 6, control lymphoblast-cell ex-
tract. Whereas the results for the T243I allele were con-
sistent when expression in E. coli and immunoblot anal-
ysis was compared, the findings for alleles L265P, L264F,
and I268T were discordant in the two methods of
analysis.
Discussion
We report four disease-causing mutations responsible
for MKD. Identification of a mutation in the Mennonite
population may provide a useful tool for detection of
heterozygotes in Mennonites, a population in which
founder effects for rare disease is well documented (for
example, maple-syrup urine disease). The observation
that the one Mennonite patient and the “putative”Men-
nonite patient were both compound heterozygotes ar-
gues against the I268T allele being a main mutation.
The I268T mutation had been overlooked in our earlier
study in which the N301T mutation had been identified.
Because of the presence of this allele in the Mennonite
population, we wanted to verify that the I268Tmutation
was functionally deleterious.
I268T results in a significant decrease in MKase ac-
tivity (to 20% of control values) upon bacterial expres-
sion (table 1). This allele was followed-up through four
generations (30 individuals) on the maternal side of the
index patient’s family, with close association between its
presence and individuals with intermediate levels of leu-
cocyte MKase enzyme activity (fig. 1). Enzymatic anal-
ysis alone represents an imprecise method for determi-
nation of the heterozygous condition; thus, we used
enzymatic methods in conjunction with direct DNA se-
quencing to verify the I268T mutation, with good cor-
relation between the two techniques (fig. 1). Recombi-
nant I268T-containing MKase had considerably higher
residual activity than the other threemutations presented
in this report (table 1). Although the second allele is
currently unknown in patient 4, heterozygotes carrying
the N301T allele often displayed !50% residual MKase
enzyme activity, suggesting that the N301T is a domi-
nant-negative mutation (Gibson et al. 1989).
I268T was found only in the heterozygous condition
in our studies, which suggested the possibility that I268T
homozygotes could be asymptomatic with sufficient re-
sidual activity for pathway function. Thus, for our two
patients, symptoms would be expected only when the
I268T allele was coupled with a null mutation (i.e., in
the case of the index patient, the N301T allele). How-
ever, this hypothesis is not supported by the recent de-
tection of an apparently unrelated patient who is ho-
mozygous for the I268T mutation and presents with
severe symptoms and almost complete MKD (Houten
et al. 1998). Nonetheless, it will be of interest to deter-
mine the incidence of the I268T allele in the Mennonite
population, especially since this allele is appearing to be
a somewhat more common mutation.
The four mutations described in the current report
bring the total number of mutations identified in MKD
to six (Schafer et al. 1992; Hinson et al. 1997a). A num-
ber of interesting points about MKD can be inferred
from our studies. With the exception of two previously
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Figure 3 SDS-PAGE analysis of wild-type and mutant recombinant MKase proteins after bacterial expression and purification on glu-
tathione Sepharose beads. The size of the fusion protein of MKase with glutathione S-transferase is 74 kDa. Lane contents are as follows: lane
1, wild type; lane 2, T243I mutant; lane 3, L265P mutant; lane 4, wild type; lane 5, I268T mutant; lane 6, L264F mutant; and lane 7, BSA
(molecular weight 68 kDa), as control. Each lane contained 8–12 mg total purified protein extract isolated from bacterial sonicates. For lanes
3, 5, and 6 the majority of protein was unfused glutathione S-transferase, which electrophoresed at an Mr of 31 kDa near the bottom of the
gel (not shown). For enzyme-specific–activity estimations, only the area of the band at Mr 74 kDa, determined by densitometric scanning, was
used to determine the final residual MKase specific activity for each preparation.
Figure 4 Alignment of MKase amino acid sequence from six
species. Amino acids 239–318 are shown. Numbering corresponds to
human amino acid sequence. Bold-type letters indicate inherited mu-
tations identified in the current report, in addition to the original
N301T allele. A. Thal  A. thaliana; S. pombe  S. pombe; S. cer. 
S. cerevisiae; M. thermo  Mycobacterium thermoautotrophicus. To
aid in alignment between species, gaps have been introduced (dashes).
The A334T mutation (table 1) is not shown.
reported siblings, all patients appear to be compound
heterozygotes, suggesting the inheritance of very rare
alleles in the human population. This is consistent with
the low number of patients that have been thus far iden-
tified. The latter observation is further supported by the
inheritance of the I268T allele, which is only one of two
alleles in the Mennonite patient and also in the patient
in whom ancestry infers a Mennonite background. Hap-
lotype analysis is currently underway in patient 1 and
4 to determine whether they inherited the same mutant
allele or if there were two independently-inherited
mutations.
Close analysis of table 1 indicates that of six reported
mutations only one (A334T) involves a CpG dinucleo-
tide, which contrasts with the observation that ∼30%
of human mutations occur in CpG doublets. This finding
is also odd in view of the fact that MKase is a relatively
GC-rich gene. Although the patient number still remains
quite low, this observation may be explained by ascer-
tainment bias, since many MKase-deficient patients may
escape detection, or the disease may be lethal in utero.
Conversely, the mutation frequency may be very low, or
the gene is hypomethylated such that mutations in CpG
dinucleotides are infrequent. In any event, analysis of
additional patients will provide insight into these
questions.
To understand the effect of inherited mutations on
protein function, especially the association of the high
residual-enzyme activity associated with the I268T allele
and the severe disease it causes, it may be useful to con-
sider the biology of MKase. MKase, an extremely hy-
drophobic homodimeric protein, historically has been
considered a cytosolic protein, although recent evidence
suggests a peroxisomal location (Tanaka et al. 1990;
Biardi et al. 1994). MKase contains a consensus-per-
oxisome–targeting sequence (PTS), located in the N-ter-
minal region, but there have been no reports to date
demonstrating targeting to peroxisomes (Biardi et al.
1994). Because none of our mutations affect this PTS,
it is unlikely that putative peroxisomal targeting is dis-
rupted in the disease state. It remains possible that
MKase might be membrane-limited, perhaps enabling
certain mutations to result in abnormal localization
more than abnormal intrinsic (decreased) activity of the
enzyme. This might be the case for the I268T allele.
Immunoblotting of MKase from cultured cells of pa-
tients, under denaturing conditions, indicated that
MKase was grossly intact and produced in levels com-
parable to control (fig. 5). While these data corroborated
those for the T243I allele expressed in E. coli, they were
discordant with the data of figure 3 for alleles I268T,
L264F and L265P, in which expression of the fusion
proteins between MKase and glutathione S-transferase
resulted in moderately to significantly decreased pro-
duction of recombinant protein. In previous work, Ta-
naka and coworkers transiently expressed recombinant
MKase from patient 1, the index patient, using COS-7
cells (Schafer et al. 1992). In those studies, the amount
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Figure 5 Immunoblot analysis of cell extracts derived from cul-
tured fibroblasts or lymphoblasts of patient 1, 2, 3a 3b, and 4 (table
1). The primary antibody was an antipeptide antibody raised in rabbit
against the C-terminal region of the MKase polypeptide. For com-
parison with figure 3 and table 1, lane contents were as follows: lane
1, patient 1 (alleles N301T and I268T); lane 2, patient 2 (alleles L265P
and T243I); lane 3, patient 4 (allele I268T and second allele unknown);
lane 4 and 5, patient 3a and 3b (allele L264F and second allele un-
known); and lane 6, control.
of MKase protein for patient 1, detected by immunoblot
of the expressed recombinant protein, was comparable
to controls although residual enzyme activity was ∼17%
of wild type. These data are consistent with our im-
munoblot analyses of the same patient and suggest that
the decreased amount of protein for I268T, L264F, and
L265P proteins may relate specifically to material ex-
pressed from E. coli. Because all of these analyses were
performed under denaturing conditions, we cannot rule
out the possibility that subunit interactions are altered
by some (or all) of the mutations we have identified.
However, our immunoblot data suggests that the gross
tertiary structure of the MKase protein in patient cell
lines is intact, suggesting that decreased enzyme activity
may relate to alterations in the enzyme active-site mi-
croenvironment. Some of these questions will be ad-
dressed more fully when the crystal structure of the
MKase protein is completed.
Sequence alignment of MKase from six species (fig.
4) reveals that three of four mutations reported here
involve relatively well-conserved branched-chain amino
acids in a mutation cluster. As shown in figure 4,
branched-chain amino acids (leucine, isoleucine, or val-
ine) occupy 15 of 18 positions corresponding to amino
acids 264, 265, and 268 of the human polypeptide.
When there is no branched-chain amino acid in three
species, hydrophobic amino acids (methionine or phe-
nylalanine) substitute. Our finding that substitution of
these hydrophobic amino acids with other amino acids
(proline or threonine) results in decreased MKase activ-
ity indicates that hydrophobicity within this region may
be important for enzyme function or dimer association.
This is also consistent with the high index of hydropathy
for rat and human MKase, a surprisingly hydrophobic
protein considering that it is predicted to be soluble or
peroxisomally located (Tanaka et al. 1990; Biardi et al.
1994; Hinson et al. 1997a).
Figure 4 shows an absolute conservation of threonine
243 and asparagine 301 between species. Isoleucine 268
is conserved between human, rat, and Schizosaccharo-
myces pombe,whereas leucine 264 is conserved between
human and rat. Leucine 265 is conserved between hu-
man, rat, and Saccharomyces cerevisiae. None of these
amino acids associated with inherited defects in MKD
lie within the highly conserved A–D elements reported
for MKase (Potter et al. 1997). In addition, none of these
mutations affect charged amino acids that might be ex-
pected to act in enzyme catalysis and/or charge transfer.
Miziorko and colleagues have convincingly demon-
strated that lysine 13 and glutamate 193 are involved
in binding of MgATP in the MKase active site, whereas
aspartate 204 is involved in enzyme catalysis (Potter and
Miziorko 1997; Potter et al. 1997). None of our inher-
ited mutations involve these residues. Sequence com-
parison of amino acid residues 240–270 of the MKase
coding sequence—a mutational cluster suggested by our
work—against other available sequences in the protein-
sequence databases reveal that this region is well con-
served only in MKase from other species and is not iden-
tified in substantive form in any other known proteins.
Preliminary attempts to correlate phenotype with ge-
notype in MKD have not been satisfactory. As in other
disorders, the expressed recombinant protein with the
least residual activity does not necessarily occur in the
most-severely affected patient. One of the least-active
proteins identified in our work was the L264F allele,
and the three siblings who carry this allele are more
mildly affected than the other three patients in whom
mutations were identified. Additional substrate-affinity
analyses of each mutant protein may provide further
insight. In addition, MKase is a dimeric protein, and all
but two MKD patients analyzed are compound heter-
ozygotes. It is difficult to predict the effect of compound
mutations when each is expressed and analyzed as a
single homozygous allele. Although all mutations iden-
tified thus far in MKD appear to cluster between amino
acids 243 and 334, residing in the C-terminal portion
of the MKase amino acid sequence, there is no single
prevalent allele. The identification of additional muta-
tions responsible for MKD, and determination of the
exact effect of these mutations on enzyme folding and
catalytic activity, may provide novel insight into struc-
ture/function relationships in MKase.
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